Delayed Neuroprotection In the Era of Hypothermia: What Can We Add?


  • Dr. Bipin Rathod
  • Dr. R. B. Kothari
  • Dr. G. B. Misal
  • Dr. D. V . Kulkarni
  • Dr. Sunil Natha Mhaske
  • Dr. Thaslima K


Erythropoietin, Hypothermia, Neuroprotection, Perinatal asphyxia


Despite the successful clinical translation of therapeutic hypothermia for perinatal encephalopathy into routine care, treatment is only partially effective. It is likely that this reflects the formidable challenges of initiating treatment for neonatal encephalopathy within a few hours after birth. In randomized controlled trials, cooling has been typically initiated at a mean 4 to 5 h after birth. This is clearly not optimal given accumulating evidence that cooling is significantly more effective when it can be initiated before 3hr. In this review we propose that given the consistent evidence that milder hypoxic-ischemic injury is associated with slower evolution of damage, any future clinical trials of delayed treatment starting more than 6hr after an insult should target infants with milder encephalopathy. We then critically examine the evidence that erythropoietin is one of the most promising preclinical candidates either for co-treatment with the mild therapeutic hypothermia or to support neuroregeneration after the therapeutic window for acute neuroprotection.


Download data is not yet available.


Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013,1:CD003311.

Thoresen M, Tooley J, Liu X, Jary S, Fleming P. Luyt K, et al. Time is brain: Starting therapeutic hypothermia within three hours after birth improves motor outcome in asphyxiated newborns. Neonatolog 2013;104:228-33.

Robertson NJ, Tan S, Groenendaal F, van Bel, F. Juul SE, Bennet L, et al. which neuroprotective agents are ready for bench Bedside translation in the newborn infant? J Pediatr 2012;160:544-52.e4

Edwards AD, Brocklehurst P, Gunn AJ, halliday H Juszczak E, Levene M, et al. Neurological outcome at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: Synthesis and meta-analysis of trial data BMJ2010;340:c363.

DuPont TL, Chalak LF, Morriss MC. Burchfield PJ, Christie L, Sánchez PJ. short-term Outcomes of newborns with perinatal acidemia who are not eligible for systemic hypothermia. J Pediatr 2013;162:35-41

Smit E, Liu X, Jary S, Cowan F, Thoresan M, Cooling neonates who do not fulfil the standard cooling Criteria - Short-and long term Outcomes. Acta Paediatr 2015,104:138-45

Thompson CM, Puterman As Linley LL, Hann FM, van der eist CW, Molteno CD et al. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome Acta paediar 1997;86:757-61.

Nagy Z, Lindström K, Westernberg H. Skare S, andersson

J, Hallberg B, et alDiffusion tensor imaging on teenagers, born at term which moderate hypoxic-ischemic encephalopathy Pediatr Res 2005;58:936-40.

Guan J, Gunn AJ. Sirimanne ES tuffin J. gunning MI, Clark R, et al. the window of opportunity neuronal rescue with insulin like growth factor-1 after hypoxia-ischemia in rats is crtically modulated by cerebral temperature during recovery. J Cereb Blood Flow Metab 2000:20:513-9.

Denker SP, Ji S, Dingman A, Lee SY, Derugin N, Wendland MF, et al, Macrophages are Comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J Neurochem 2007;100:893-904

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev immunol 2008,8:958-69.

Imai F, Suzuki H, Oda J, Ninomiya , Ono K, Sano H, et al. Neuroprotective effect of exogenous microglia in global brain ischemia J Cereb Blood Flow Metab 2007;27:488-500.

Nijboer CH. Heijnen CJ, Groenendaal F, May MJ, van Bel F Kavelaars A. A dual role of the NF-kappaB pathway in neonatal hypoxic is chemic Brain damage. Stroke 2008;39:2578-86.

Juul SE, Anderson DK, LI Y Christensen RD, Erythropoietin and ervthropoietin receptor in the developing human central nervous system pediatr Res 1998:43:40-9.

Fauchere JC, Dame C. vonthein R, koller B, Arri S, wolf M, et. al. An Approach to using recombinant erythropoietin for neuroprotection in very preterm infants. pediatrics 2008;122:375-82.

Rogers EE, Bonificio Sl, Glass HC, Juul SE, Change T, mayock DE, et al. Erythropoietin and hypothermia for hypoxic ischemic encephalopathy. pediatr Neurol 2014;51:657-62

Elmandy h, El Mashad AR, El-Bahrawy H, El gahary T, El-Barbary A. Aly H, Human recombinant erythropoitin inasphyxia feonatorum pilot trial. pediatrick 2010;125:e1135-42

Benders MJ, van Der Aa NE, Roks M, van Straaten HL, isgum I, viegever MA, et al. Feasibility and safety of erythropoitin for neuroprotection after perinatal arterial ischemic stroke. J padiatr 2014;1e1-2.




How to Cite

Rathod, D. B. ., Kothari, D. R. B., Misal, D. G. B., . Kulkarni, D. D. V., Mhaske, D. S. N., & Dr. Thaslima K. (2017). Delayed Neuroprotection In the Era of Hypothermia: What Can We Add?. VIMS Health Science Journal, 4(1), 52–55. Retrieved from



Review Articles

Most read articles by the same author(s)

1 2 3 > >>